102 related articles for article (PubMed ID: 30532864)
1. Repetitive early stent thrombosis in a patient with the CYP2C19*3/*3 genotype.
Takashio S; Hokimoto S; Kaikita K; Fujimoto K; Misumi I; Nakagawa K; Ogawa H
J Cardiol Cases; 2011 Aug; 4(1):e16-e19. PubMed ID: 30532864
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism.
Afzal A; Patel B; Patel N; Sattur S; Patel V
Case Rep Med; 2016; 2016():2312078. PubMed ID: 27555873
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
[TBL] [Abstract][Full Text] [Related]
4. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
5. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Wei YQ; Wang DG; Yang H; Cao H
PLoS One; 2015; 10(7):e0132561. PubMed ID: 26147597
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S
Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G
Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G
Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981
[TBL] [Abstract][Full Text] [Related]
10. Very late stent thrombosis occurring simultaneously in sirolimus-eluting stents and bare-metal stent in three different coronary vessels.
Kawaguchi Y; Katayama J; Kumazawa A; Sugiyama H; Watanabe T; Wakahara N
Cardiovasc Interv Ther; 2011 Jan; 26(1):64-9. PubMed ID: 24122502
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
[TBL] [Abstract][Full Text] [Related]
12. Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
Ichikawa M; Takei Y; Hamasaki T; Kijima Y
Circ J; 2015; 79(1):85-90. PubMed ID: 25744629
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
Dick RJ; Dear AE; Byron KA
Heart Lung Circ; 2011 Oct; 20(10):657-8. PubMed ID: 21215696
[TBL] [Abstract][Full Text] [Related]
14. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
15. Early double stent thrombosis associated with clopidogrel hyporesponsivenesss.
Rademakers LM; Dewilde W; van de Kerkhof D
Neth Heart J; 2012 Jan; 20(1):38-41. PubMed ID: 21604104
[TBL] [Abstract][Full Text] [Related]
16. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
17. Late stent thrombosis in a patient with CYP2C19*3/*17 genotype and clopidogrel high on-treatment platelet reactivity.
Tan SSN; Koh KT; Tiong LL; Ong TK; Fong AYY
Pharmacogenomics; 2018 Oct; 19(15):1151-1157. PubMed ID: 30191759
[TBL] [Abstract][Full Text] [Related]
18. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
[TBL] [Abstract][Full Text] [Related]
19. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
